Navigation Links
Sanofi US Launches Second Innovation Challenge: Collaborate | Innovate

BRIDGEWATER, N.J., Dec. 9, 2013 /PRNewswire/ -- Today, Sanofi US launched its second Partners in Patient Health (PiPH) Innovation Challenge: Collaborate | Innovate, which will award $100,000 to the winning team. This year's theme is "Co-Creating for Breakthroughs: Moving toward a collaborative research and development ecosystem." The Challenge calls on non-profit patient, provider and professional associations to partner with other associations and/or academic institutions to propose new approaches which translate patient insights into improvements in the drug development process.


A treatment breakthrough can cost billions of dollars and decades of time to research. Patient organizations are in the position of helping patients and their constituents to play an important role in research and development (R&D). Patient involvement in the entire process can lead to improvements in efficiency and effectiveness of industry efforts in developing new therapies.

"Patients can influence each phase of the R&D process from initial drug discovery, to clinical trial development, participation and post-approval monitoring," said Marc Bonnefoi, Head of North America R&D at Sanofi. "This year's Innovation Challenge will promote collaboration across a diverse community of patient advocates to put patients at the heart of the R&D process, which can ultimately improve their health outcomes and those of others who will benefit from access to new and innovative solutions."

For consideration, the entries must meet the following criteria:

  • Proposed ideas should focus on translating patient insights into improvements in the various stages of drug development.
  • Submissions should include measurable goals with a clear view toward creating a proof-of-concept.
  • The primary entrant must be a non-profit patient, provider or professional association partnering with one or more of the following: another non-profit patient, provider or professional association and/or an academic institution. A multidisciplinary approach is highly encouraged. All team members must be legally based in the U.S.

The submission period will remain open until February 23, 2014 and four finalist teams will be announced on March 17th. The four Challenge finalists will enter into a Virtual Accelerator stage, which includes a period of rigorous mentorship with industry experts. Final judging will take place in April 2014.

The first PiPH Innovation Challenge, launched in 2012, saw a tremendous response, including 128 submissions from more than 280 partnering organizations that were motivated to help patients engage in their health across a broad range of therapeutic areas. The winner, Registries for All Diseases, received an award to create a comprehensive, crowdsourced, cross-disease registry to help accelerate translational research for over 1,000 diseases. The winning team consisted of partnering organizations Genetic Alliance, CFIDS Association of America, National Psoriasis Foundation, and the Inflammatory Breast Cancer Research Foundation.

"The Challenge was incredibly meaningful for us. In addition to the value of the award, which enabled us to move our initiative forward, the Challenge gave us exposure to other groups and allowed us to build relationships," said Sharon Terry, President and CEO of Genetic Alliance. "Creating patient-centered solutions can empower people to participate in their own health and contribute to advancements in care."

For a complete list of Innovation Challenge rules, and to submit a concept,

To follow the Challenge as it progresses, follow us:

Sanofi US "Partners in Patient Health"

The PiPH Innovation Challenge: Collaborate | Innovate is an initiative of Sanofi US's Partners in Patient Health team within US Corporate Affairs. PiPH is leading a novel approach to partnering with the advocacy community by connecting people, ideas, and solutions to focus on critical issues that are of high importance and common across a wide range of advocates dedicated to advancing patient health.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US. For more information on Sanofi US, please visit or call 1-800-981-2491.

Sanofi US is also on Twitter and Facebook. Visit us at and

Brandi Robinson
Vice President, NA Communications
Tel: 908-989-0726

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
2. Zacks Industry Outlook Highlights: Merck, Pfizer, Forest Laboratories, Sanofi and Eli Lilly
3. Sanofi Announces New Phase 3 Results for Investigational New Insulin U300
4. Sanofi and Regenerons Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence
5. Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
6. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
7. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
8. Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
9. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
10. Sanofi Pasteur Announces Shipment of First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.
11. Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... Chicago, IL (PRWEB) , ... November 27, 2015 ... ... some of the largest, most successful and prominent nonprofit healthcare organizations in the ... and governance involvement with various organizations, and helped advance the healthcare industry as ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Avid collector, ... Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most famous ... Canterbury House at the University of Michigan in Ann Arbor. The According to Hawley, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
Breaking Medicine News(10 mins):